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Abstract
Objective: To report oncological outcomes and toxicity rates, of definitive platin-based chemoradiadiationtherapy
(CRT) in the management of proximal esophageal cancer.
Methods: We retrospectively reviewed the medical records of patients with cT1-4 cN0-3 cM0 cervical esophageal
cancer (CEC) (defined as tumors located below the inferior border of the cricoid cartilage, down to 22 cm from the
incisors) treated between 2004 and 2013 with platin–based definitive CRT in four Swiss institutions. Acute and
chronic toxicities were retrospectively scored using the National Cancer Institute’s Common Terminology Criteria for
Adverse Events, version 4.0 (CTCAE-NCI v.4.0). Primary endpoint was loco-regional control (LRC). We also evaluated
overall survival (OS) and disease-free survival (DFS) rates. The influence of patient- and treatment related features
have been calculated using the Log-rank test and multivariate Cox proportional hazards model.
Results: We enrolled a total of 55 patients. Median time interval from diagnosis to CRT was 78 days (6–178 days).
Median radiation dose was 56Gy (28–72Gy). Induction chemotherapy (ICHT) was delivered in 58% of patients. With
a median follow up of 34 months (6–110months), actuarial 3-year LRC, DFS and OS were 52% (95% CI: 37–67%),
35% (95% CI: 22–50%) and 52% (95% CI: 37–67%), respectively. Acute toxicities (dysphagia, pain, skin-toxicity)
ranged from grade 0 – 4 without significant dose-dependent differences. On univariable analyses, the only
significant prognostic factor for LRC was the time interval > 78 days from diagnosis to CRT. On multivariable
analysis, total radiation dose >56Gy (p <0.006) and ICHT (p < 0.004) were statistically significant positive predictive
factors influencing DFS and OS.
Conclusion: Definitive CRT is a reliable therapeutic option for proximal esophageal cancer, with acceptable
treatment related toxicities. Higher doses and ICHT may improve OS and DFS and. These findings need to be
confirmed in further prospective studies.
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Introduction
Cervical esophageal cancer (CEC), located between the
cricopharyngeal muscle and the sternal notch, repre-
sents < 5% of all esophageal cancers [1]. In contrast to
the middle and lower esophageal cancer, for which
chemo-radiotherapy (CRT) is the standard of care, for
both, in the neo-adjuvant and definitive setting [2–5],
the management of CEC remains controversial. In the
past, patients with CEC underwent surgery, including
pharyngo-laryngo-esophagectomy [6], resulting in per-
manent tracheostomy, impacting the quality of life of
these patients enormously [7]. Five-year overall survival
(OS) rates with surgery alone are poor, ranging between
12 – 27%, while operative morbidity is substantial (29–
55%) [1]. Due to its anatomical proximity to the hypo-
pharynx, as well as its common etiology, CEC is usually
treated in analogy to hypopharyngeal cancer [8] or
standard esophageal cancer protocols [9]. Randomized
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trials of esophageal cancer and squamous-cell carcinoma
(SCC) of the head and neck have demonstrated
improved survival with CRT compared to radiotherapy
(RT) alone. However, these trials have not included CEC
[6, 9–11]. There are no prospective clinical trials to guide
treatment in CEC. Retrospective studies evaluating the
role of definitive CRT are scarce [6, 12–19]. Five-year OS
following definitive RT alone ranges between 15 and 32%
[1], while definitive CRT can achieve 5-year OS rates up to
55% with mean total radiation doses ranging from 61.2 to
66Gy, with acceptable toxicity [20]. As a result, RT or
CRT have emerged as the preferred treatment modalities
for SCC of the upper esophagus. However, no consensus
has been reached, with regards to the optimal sequence of
CRT, nor which RT dose should be delivered. A lot of pa-
tients are treated using institutional protocols. The aim of
the current multicenter study is to report the oncological
outcome and toxicity rates of definitive external beam RT
combined with platin-based chemotherapy, with a particu-
lar focus on the impact of RT dose and sequence of
chemotherapy (CHT).
Materials and methods
Medical records of patients with CEC treated between
2004 and 2013 with definitive CRT in four Swiss institu-
tions were retrospectively analyzed. The analysis in-
cluded non-metastatic patients with a pathologically
confirmed CEC. We defined a CEC as a tumor of the
esophagus located between the inferior border of the cri-
coid cartilage to 22 cm from the incisors. Patients with
prior CRT or secondary cancers either synchronously or
within the past five years were excluded. All patients
were treated according to institutional protocols, con-
sisting of either platin-based induction chemotherapy
(ICHT), concurrent platin-based CRT or both. If ICHT
was administered, a platinum-based regimen [21] was
used. Concurrent chemotherapy was administered using
regimens that included cisplatin and 5-fluorouracil (5-
FU), oxaliplatin and 5-FU or carboplatin and paclitaxel
[22, 23]. If the Cisplatin/5-FU regimen was given, each
cycle of CHT was given on days 1 and 29 and 5-FU was
administered as a continuous intravenous infusion after
completion of the cisplatin on days 1 through 4 and 29
through 32. Concurrent platin plus taxane based CHT
was given weekly up to 6 cycles. Target delineation was
based on international consensus guidelines [24]. Con-
touring was carried out on CT scans with a slice thick-
ness of 2–3 mm and included information from PET
scans and endosonography.
Toxicity assessment and follow-up
Patients were clinically assessed on a weekly basis during
CRT, at which time point laboratory parameters (such as
hemoglobin, leukocytes, platelets and renal function)
were reviewed. The first clinical follow up visit was per-
formed 4 to 6 weeks after completion of treatment,
afterwards, every three months in the first two years, six
months the third year and annually thereafter. Each
follow-up included a physical examination and blood
work (hemoglobin, leukocytes, platelets, renal function
and hepatic function). Diagnostic CT including neck/
thorax/abdomen and endoscopy took place every six
months during five years and thereafter annually. PET/
CT was performed, when clinically indicated. All ob-
served adverse events were graded according to the Na-
tional Cancer Institute’s Common Terminology Criteria
for Adverse Events, version 4.0 (CTCAE-NCI v.4.0) [25].
Statistical analysis
Pseudonymized multi-institutional patient data were
pooled in a central database. Time to event data was cal-
culated from the first day of RT until the last follow up
or until death using the Kaplan-Meier method. Loco-
regional control (LRC) was defined as the absence of
tumor progression in the treatment volume on follow-
up. Disease-free survival (DFS) was defined as time until
local or distant disease relapse after treatment or death
due to any cause. Overall survival was defined as time
from diagnosis until death from any cause The Log-rank
test was used for univariable analysis (UVA) for continu-
ous prognostic factors, the median value was used for
grouping and the Cox proportional hazard model was
used for multivariable analysis (MVA). The Linear-by-
Linear Association test was used to compare toxicities.
A significance level of p = 0.05 was used; all tests were
two- sided. Factors having a p-value ≤ 0.20 in UVA and
technical related factors of interest, such as RT dose,
have been included in MVA. The MVA models for LRC,
DFS and OS were created using backward selection.
Statistical analysis was performed using JMP 10.0 statis-
tical software (Cary, NC).
Ethics
All patients gave informed consent prior to initiation of
treatment. Research ethics board approval was obtained
for this analysis (PB_2016-01147). This work is in ac-
cordance with the Declaration of Helsinki in its most re-
cent version.
Results
Patients’ characteristics
Fifty-five patients were meeting the inclusion criteria of
this study. Forty-two patients (76%) were male and the
mean age was 64 years (42–78 years). Median follow-up
was 34 months (6-110 months). Baseline patient charac-
teristics are shown in Table 1. During the investigated
period (2004-2013) the irradiation technique changed
how esophageal carcinomas are treated. It shifted from
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3-D to IMRT technique. Fig. 2 gives an overview of the
patients treated per year. Yet, some patients continued
to be treated with 3-D technique. Ninety percent of pa-
tients presented with dysphagia before treatment, scored
as grade 1, 2 and 3 in 36%, 40% and 14%, respectively.
The majority of patients presented with a locally ad-
vanced tumor (76% cT3-4 and 67% cN+). Median pri-
mary tumor length was 5 cm (1 – 14 cm). All but four
patients had biopsy-proven SCC; the remaining patients
presented a carcinoma in situ (n = 1), an adenocarcin-
oma (n = 1), and in two patients histology was not
conclusive.
Radiotherapy
Median time interval from diagnosis to RT was 78 days
(6-178 days). RT was delivered either in a single, or two
courses (boost). Single doses from 1.2 to 5Gy were used.
Twenty-one patients (38%) were irradiated using con-
ventional 3-D, and 34 patients (62%) with intensity-
modulated RT (IMRT). Median cumulative RT dose was
56Gy (28–72Gy). Fifty-three patients (96%) received ex-
ternal beam RT alone. Two patients (4%) received
50.4Gy, using IMRT with a boost delivered using high
dose rate brachytherapy (HDR-BT) (2 × 3Gy), up to a
total dose of 56.4Gy.
Chemotherapy
Thirty-two patients (58%) received induction chemo-
therapy (ICHT), mainly delivered with platin-based regi-
mens (cisplatin, n = 10, carboplatin n = 22) combined
with 5-fluorouracil (5-FU, n = 10) or with taxanes (n =
22). Median number of cycles ICHT was two (0–4 cy-
cles). The same CHT regimens were delivered concur-
rently to RT in 51 patients (93%). Four patients did not
receive concurrent CRT because of hematological toxic-
ities after ICHT (n = 3) and patient refusal (n = 1).
Toxicity
Most frequent radiation-related acute toxicities included
dysphagia, pain and skin-reactions. Grade 2 dysphagia
occurred in 45% of patients. Higher-grade dysphagia
(grade ≥3) was reported in 15% of patients. Eighty-two
percent of patients experienced pain (odynophagia)
throughout radiotherapy. Grade 1, 2 and 3 odynophagia
Table 1 Baseline Characteristics
Characteristic Number of patients [N]
Age (years), median (range) 64 (42-79)
Gender
Male 42
Female 13
Pathological grade
G 1-2 21
G 3 11
Gx/NA 23
Pathology
Squamous cell 52
Adenoid cell 1
CIS/NA 1/1
T stage
≤ 2 12
3-4 42
Tx 1
N stage
N 0 18
N 1-3 37
TNM stage
I-II 20
III 34
NA 1
Radiation dose (Gy)
< 56 26
≥ 56 29
Radiotherapy technique
3D 14
IMRT 24
Tomotherapy 17
Induction chemotherapiy
Yes 32
No 23
Concurrent chemotherapy
Yes 51
No 4
Acute Tox≥ Grade 3
Dysphagia 8
Skin 3
Pain 7
Haematological 5
Chronic Dysphagia
Grade 1-2 30
Grade 3-4 5
Table 1 Baseline Characteristics (Continued)
NA 20
Patients by center
Bern University Hospital 16
Hôpitaux Universitaires de Genève 7
Centre Hospitalier Universitaire Vaudois 16
Kantonsspital St.Gallen 16
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were reported in 42 , 27 and 12%. ICHT had no impact
on odynophagia (p = 0.76). Unfortunately, no data on
pre-treatment odynophagia levels were available. Acute
skin toxicity was assessed in all patients, grade 1, 2 and
3 skin reactions were reported in 29 , 15 and 5%, re-
spectively. The remaining patients (51%) showed no
signs of acute skin toxicity. In the group of patients,
which received ICHT, only 6% presented with a grade 2
and 3% with a grade 3 skin reaction, whereas 26% of pa-
tients treated without ICHT had a grade 2 and 9% had a
grade 3 skin toxicity, even though no statistical differ-
ence was found in the two groups (p = 0.05).
Grade 1, 2 and 3 CHT-associated hematological toxic-
ities were reported in 20 , 33 and 9% of the population,
respectively. Within the group of patients with ICHT,
grade 2 hematological toxicities were significantly higher
(p = 0.04), but no differences in incidence of severe
(grade 3+) toxicity were seen (11 vs. 13%, p = 0.87).
Only two patients (4%) needed hospitalization for
treatment-related toxicity (one patient for uncontrolled
dysphagia and one for tumor bleeding). One patient
(2%) was hospitalized for his brachytherapy boost and
one patient (2%) was hospitalized because of installation
of a Witzel fistula.
At last follow up, 33% of patients had no signs of dys-
phagia; grade 1, 2 or 3 dysphagia was observed in 13%,
11% and 9%. Noteworthy, no data on late esophageal
toxicity were available in 18 patients (32%).
Patterns of failure
Thirty-three patients (60%) had developed a treatment
failure consisting of 31% isolated local failure (n = 17),
11% isolated systemic failure (n = 6) and 29% combined
local and distant failure (n = 16), Noteworthy, 38% (n =
21) of patients had no treatment failure. In one patient
(2%) no data were available about patterns of failure.
Treatment outcome
At last follow up, 28 patients (51%) were still alive.
Three-year actuarial LRC, DFS and OS in the total co-
hort were 52% (95% CI: 37–67%), 35% (95% CI: 22–50%)
and were 52% (95% CI: 37–67%), respectively (Figs. 1, 2
Kaplan-Meier curves for LRC, OS, DFS) For the patients
receiving ICHT (n = 32), three-year LRC, DFS and OS
were 60 , 43 and 60%, respectively. Three-year LRC, DFS
and OS for patients without ICHT (n = 23) was 40 , 25 ,
and 40%, respectively. The difference in outcomes was
not statistically significant (p > 0.10), since the number
of patients in each group (ICHT vs. non-ICHT group)
was small. On UVA (Table 2) longer time interval (>78
vs. <78 days) from diagnosis to CRT was a significant
predictive prognostic factor for DFS (p =0.03). After
backwards selection, MVA (Table 3) revealed that cumu-
lative radiation dose >56Gy and ICHT were independent
positive predictive factors for DFS [(p < 0.03) and (p <
0.02), respectively], and OS [(p < 0.006) and (p < 0.004),
respectively]. T and N categories were not statistically
significant predictive prognostic factors for LRC, DFS or
OS (p >0.05).
Discussion
In the present study, we report results from a multicen-
ter cohort of CEC patients treated with definitive CRT,
with or without ICHT. No prospective clinical trials
exist in CEC to guide treatment. Few retrospective stud-
ies were published, illustrating the outcomes of definitive
CRT in CEC. These series were heterogeneous in terms
of RT techniques, CHT regimens, and radiation doses.
Approximately 59% of patients within these reports [6,
13, 15, 19, 26–28] received RT alone, and 41% received
CRT [7, 13, 14, 16, 19, 26–29]. When a concurrent treat-
ment approach was chosen, 22% of these patients re-
ceived ICHT [16, 20, 29]. Three-year OS rates of 24–
58% were reported in CEC patients treated with defini-
tive RT, with or without CHT following short-term ob-
servation [12, 15, 16, 20, 29]. Table 4 gives an overview
of the so far published outcome data of CEC patients
treated with RT alone or RCT with or without ICHT. In
our cohort, 3-years actuarial LRC, OS and DFS were
52% (95% CI: 37–67%), 35% (95% CI: 22–50%) and 52%
(95% CI: 37–67%), respectively (Fig. 1a–c), and conse-
quently is well comparable with the existing data. More-
over, longer time interval (≥78 vs. <78 days) from
diagnosis to RT was a significant prognostic factor for
DFS (p = 0.03). Since 58% of patients (n = 32) in our study
have received ICHT, which prolongs time interval to CRT,
we hypothesize ICHT could be an indicator for its impact
on DFS. Therefore, we have included ICHT into MVA.
After backwards elimination, ICHT was a significant
predictive factor for DFS (p < 0.02) and OS (p < 0.004).
Stuschke et al. [16] published in 1999 their data on 17
CEC patients treated with ICHT followed by concurrent
CHT and high-dose RT for locally advanced SCC CEC.
Three-year survival in their cohort was 24%. During
ICHT, patients received either treatment with 5-FU
(5FU/leucovorin/cisplatin/etoposide [FLEP protocol])
followed by cisplatin/etoposide during concurrent CRT,
or alternatively 5-FU/leucovorin/cisplatin for ICHT and
5-FU/cisplatin during concurrent CRT. Hematological
toxicities after FLEP were observed in 36% of patients.
In a follow-up study of 55 patients by the same group
[20], 3-year survival rate in patients treated with FLEP
ICHT (n = 25) was 37% and in those treated with 5-FU/
L/P ICHT (n = 22) 18%. Patients with ICHT other than
these two protocols (n = 8) had a 3-year survival rate of
31%. Differences were statistical not significant (p =
0.42). Zhang et al. [29] recently published data of 102
patients with CEC, treated with definitive CRT. Within
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Fig. 1 a-c Kaplan-Meier curves for a) Loco-regional control (LRC) b) overall survival (OS) C) disease-free survival (DFS)
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this cohort, 18 patients (17.6%) received platin- based
ICHT. In contrast to our study, for patients that received
ICHT, 3-year OS and PFS were significantly worse than
in patients who did not receive ICHT (11.1 vs. 45.5%,
p = 0.016; 11.1 vs. 40.5%, p = 0.019). Their explanation
of why ICHT was conversely related to survival was, that
17 out of 18 patients in the ICHT group had stage III dis-
ease. In our study, for patients receiving ICHT, 3-year
LRC was 41%, DFS 25% and OS 34%, which was superior
to Zhang’s and similar to Stuschke’s outcome. Most fre-
quent ICHT complications in our study included signifi-
cantly higher-grade two hematological toxicities (p = 0.04)
than the group with no ICHT. But ICHT had no impact
on increasing dysphagia, odynophagia and skin reactions
(p = 0.052). These results in CEC stand in contrast to the
experience in locoregionally advanced head and neck
squamous cell cancer (HNSCC). There ICHT remains a
subject of intense debate in the management of HNSCC.
No overall survival benefit was identified from the ICHT
[30]. The large, meta-analysis of chemotherapy on head
and neck cancer (MACH-NC) of individual patient ana-
lysis of 17,346 patients from 93 randomized trials con-
ducted between 1965 and 2000 reported first in 2000 [31]
and then updated in 2009 [11], by Pignon et al. ICHT sig-
nificantly improved the rate of distant metastases (HR,
0.73; 95% CI, 0.61 to 0.88; P = 0.001) but did not influence
locoregional failure.
With regards to the total radiation dose, there has
been a tendency in CEC - in analogy to HNSCC - to use
higher doses of radiation up to 66–70Gy. Retrospective
studies [7, 12, 15, 16, 18, 19, 29] have shown that higher
dose of radiation might be associated with improved
outcome in CEC. Zhang et al.’s [29] study revealed that
patients with stage II - III esophageal cancer treated with
concurrent CRT with a radiation dose >51Gy (54–
64.8Gy) had better LRC and OS than those treated with
≤51Gy. The median dose in the lower and higher dose
groups was 30Gy (range, 30–51Gy) and 59.4Gy (range,
54–64.8Gy), respectively. Patients in the higher dose
group had a statistically significant better 3-year LCR
(36 vs.19%; p = 0.011), DFS (25 vs.10%; p = 0.004), and
OS (13 vs. 3%; p = 0.054) rate. Wang et al. [18] reported
that OS, cause specific survival (CSS), and local relapse-
free survival (LRFS) rates were significantly higher in pa-
tients receiving a radiation dose >50Gy than in those <
50Gy. Total radiation dose was the only independent
factor associated with improved local control and OS.
Our data confirm that. Our study confirms these find-
ings: multivariate analysis showed that radiation dose
>56Gy was a significant positive predictive factor for
DFS (p = 0.03) and OS (p = 0.006). However, Huang et al.
[13] found no difference between high-dose RCT of
70Gy compared to RCT to 54Gy. They have treated
CEC patients with two different treatment protocols
with 54Gy in 20 fractions within 4 weeks, combined
with 5-FU and either mitomycin or cisplatin vs. 70Gy in
35 fractions within 7 weeks to the primary tumor and
elective nodes, with high-dose cisplatin.
Looking at other potential prognostic factors, no
consistency exists within the literature. Our study
Fig. 2 Treated patients per year
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revealed that tumor grade was a prognostic factor for
OS (p = 0.03). T and N categories were not statisti-
cally significant prognostic factors for LRC, DFS or
OS (p > 0.05). We assume, our cohort was too small
to detect a statistical significant difference. In a study
by Huang et al. [13], female gender and older age
might predict for a better outcome, but a statistical
significant difference could not be demonstrated. In
Wang et al.’s [18] study, radiation dose (>50Gy vs.
<50Gy) was the only factor associated with OS (p =
0.006), CSS (p = 0.003), and LRFS (p = 0.001) and
tumor stage was the only factor associated with DFS
(p = 0.007). In Zhang et al.’s [29] study, multivariate
Table 2 Univariate analysis of prognostic factors influencing OS, DFS, and LRC in cervical esophageal cancer
Factor 3-year LRC
(%)
p-value 3-year DFS
(%)
p-value 3-year OS
(%)
p-value
Gender
Female 51 0.71 17 0.28 42 0.2
Male 53 42 56
Age
≤ 65y 66 0.25 41 0.82 54 0.64
≥ 65y 39 30 52
Tumor grade
G2 55 0.14 44 0.34 68 0.12
G3 57 32 46
TNM
T1-2 54 0.62 26 0.27 56 0.7
T3-4 45 0.50 39 0.42 40 0.81
N0 57 44 49
N+ 50 31 53
ICHT
No 41 0.18 25 0.11 40 0.11
Yes 60 43 60
Time to RT
≤ 78days 43 0.24 24 0.03 53 0.45
≥ 78days 59 46 52
RT Modality
3-D 47 0.5 36 0.68 60 0.75
IMRT 55 36 47
Dysphagia before treatment
0 53 0.67 53 0.83 53 0.51
G1 57 34 48
G2 57 36 59
G3 29 25 37
RT dose
≥ 56Gy 56 0.76 36 0.78 56 0.88
≤ 56Gy 50 35 49
ICHT induction chemotherapy, RT radiation treatment, LRC loco-regional control, DFS disease-free survival, OS overall survival
Table 3 Multivariate analysis of prognostic factors related to
DFS, and OS in cervical esophageal cancer
Endpoint Variable HR 95% CI for HR p- value
DFS IDCHT 0.42 0.20 - 0.88 0.02
RT Dose 0.95 0.9 – 0.99 0.03
OS IDCHT 0.26 0.1 - 0.65 0.004
RT Dose 0.01 0.0006 - 0.3 0.006
Grade 0.02 0.002 - 0.46 0.033
OS overall survival, DFS disease-free survival, IDCHT induction chemotherapy,
RT Dose radiation treatment dose, 95% CI 95% confidence interval, HR
hazard ratio
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analysis revealed that gender and hoarseness were
independent prognostic factors related to OS and
PFS. Hoarseness (HR = 2.834; p = 0.002) was the only
independent prognostic factor affecting LRFFS.
Yamada et al.’s [15] study showed that performance
status (p < 0.01) and tumor length (p < 0.01) were in-
dependent prognostic factors. The role of involvement
of human papillomavirus (HPV) as a prognostic factor
in the setting of SCC esophageal carcinoma remains
unclearly defined. In oropharyngeal lesions, HPV-
positivity has shown to be a strong positive prognos-
tic factor in patient outcomes [32–35], whereas HPV
in esophageal SCC does not appear to be a significant
etiologic agent [36]. Furihata et al. [37] have shown
that, HPV infection in SCC esophageal carcinoma was
a poor prognostic indicator. In contrast, a recent
series by Cao et al. [38], showed improved overall
and disease-free survival in SCC esophageal carcin-
oma in patients with HPV- positive tumors. Several
other studies still have failed to show any significant
association between HPV infection and patient sur-
vival [39–41]. Since in the present cohort systematic
testing of the HPV status for CEC patients has not
been a standard procedure within the work up
process during the period of investigation, no data
was available for the HPV status.
As for other studies already published on this topic,
some important limitations should be acknowledged in
our study. It is of retrospective nature, and therefore, we
could underestimate the toxicity data, which is an
important considerable factor, when an intensification of
the treatment is planned (with ICHT and/or dose escal-
ation). Moreover, the multicenter data collection allowed
to increase the number of patients, but it added also
some bias related to local treatment standards. Never-
theless, we think that our study is of interest, as consid-
erable practice variations exist worldwide in using
definitive RT with or without CHT for the management
of CEC. Our results add new aspects to the data already
available in the literature. We think that it could be
hypothesis generating for a prospective study, exploring
the role of ICHT and/or dose escalation in the treatment
of CEC.
Conclusion
Results of our study confirm that definitive CRT with or
without ICHT can be considered as an alternative to
surgery in the treatment of CEC, as the 3-year outcomes
are very encouraging and the toxicity acceptable. ICHT
and cumulative RT doses > 56Gy were associated with a
better outcome. Our study supports the design of
prospective studies exploring schedules of treatment
intensification including ICHT and RT doses > 56Gy in
CEC patients.
Abbrevations
(CEC): Cervical esophageal cancer; (CHT): Chemotherapy; (CI): Confidence
interval; (CIS): Carcinoma in situ; (CRT): Chemo-radiation-therapy; (CSS): Cause
specific survival; (CTCAE-NCI v.4.0): Common terminology criteria for adverse
events, version 4.0; (DFS): Disease-free survival; (FLEP): 5FU/leucovorin/
cisplatin/etoposide; (HDR-BT): High dose rate brachytherapy; (HNSCC): Head
and neck squamous cell cancer; (HPV): Human papillomavirus; (HR): Hazard
ratio; (ICHT): Induction chemotherapy; (IMRT): Intensity-modulated radiation
therapy; (LRC): Loco-regional control; (LRFS): Local relapsefree survival;
(MVA): Multivariable analysis; (NA): Not available; (OS): Overall survival;
(PFS): Progression free survival; (RT): Radiotherapy; (SCC): Squamous-cell
carcinoma; (UVA): Univariable analysis
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